All In Biotech

NDA 020782 · Abbott

Depakote Er

Divalproex Sodium · Oral

Last checked: Nov 20, 2026Latest source record: Dec 20, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Dec 20, 2002

Approved uses

1

Original approval plus efficacy supplements

Registered trials

398

85 Phase 3, 16 recruiting

FAERS reports

46,653

31,288 serious, 2,596 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • DEPAKOTE ER · DIVALPROEX SODIUM 250MG · Tablet, Extended Release, Oral · Prescription
  • DEPAKOTE ER · DIVALPROEX SODIUM 500MG · Tablet, Extended Release, Oral · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Divalproex" as an intervention, any sponsor and status, largest first.

All 398 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,110
  • seizure2,678
  • weight increased2,181
  • nausea2,123
  • off label use2,123
  • fatigue1,981
  • somnolence1,922
  • pain1,905
  • tremor1,853
  • fall1,788
  • anxiety1,723
  • vomiting1,654

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,203
20051,347
20061,267
20071,289
20081,683
20092,925
20102,531
20112,325
20122,288
20131,971
20142,048
20152,701
20162,840
20172,368
20182,214
20192,253
20202,011
20212,122
20222,178
20231,897
20241,867
20251,954
20261,366

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Depakote ER (Divalproex Sodium)

2024 spending

$9.2M

Beneficiaries

2,044

12,774 claims

Per beneficiary

$4,488

$3.67 per unit

View as table
YearSpending
2020$19,007,051
2021$17,664,980
2022$16,317,136
2023$11,067,971
2024$9,172,919

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 302 on PubMed

Sponsor: Abbott

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.